Michael J. Ferguson

Abstract 6179: Differential sensitivity of paired FUS-TFCP2+ RMS PDX models developed from tumor specimens obtained prior to and after ALK inhibitor therapy

Erika A. Dobrota, Mohammad Reza Saadatzadeh, Barbara J. Bailey, Keiko E. Kreklau et autres

Abstract FUS-TFCP2-positive rhabdomyosarcoma (FUS-TFCP2+ RMS) is a rare subtype of spindle cell/sclerosing RMS with a craniofacial predilection. These tumors are highly aggressive, quick to metastasize and evade conventional chemotherapies. FUS-TFCP2 fusion results in a gain of function transcription factor that promotes proliferation …

us (code pays fourni par la source)

Dual CDK4/6–PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcoma

Farinaz Barghi, Mohammad Reza Saadatzadeh, Erika A. Dobrota, Harlan E. Shannon et autres

Osteosarcoma (OS) in pediatric, adolescent, and young adult (AYA) patients is an aggressive bone cancer with limited treatment options. Dysregulation of the CDK4/6-cyclin D axis and the PI3K/mTOR pathway contributes to OS pathogenesis, providing a biological rationale for co-targeting these signaling nodes. …

us (code pays fourni par la source)

Chondromyxoid Fibroma of the Nasal Cavity: A Benign Tumor in a Rare Head and Neck Location

Chelsea Onyeji, Alycia Boutrand, Michael J. Ferguson

Chondromyxoid fibroma (CMF) is a rare benign bone tumor that infrequently involves the craniofacial skeleton. Its diagnosis can be challenging due to overlapping imaging features with other lesions. We report a case of a 72-year-old female in whom a right posterior nasal …

us (code pays fourni par la source)

BIOM-02. Examination of Growth Differentiation Factor 15 (GDF15) tumor expression as a potential prognostic biomarker in pediatric brain and solid tumors

Elizabeth M. Marlowe, Michael J. Ferguson, Mark S. Marshall, Daniel Runco

Abstract Background Despite the evolving molecular characterization of pediatric tumors, treatment-related morbidity and mortality remains high. Growth Differentiation Factor 15 (GDF15), an inflammatory cytokine, facilitates tumor angiogenesis, growth, and metastasis in adults, leading to malignant progression, metastasis, and recurrence in gastric cancers …

us (code pays fourni par la source)

Abstract 2606: In vivo screening reveals therapeutic vulnerabilities in a patient-derived xenograft established from an intraosseous TFCP2-rearranged rhabdomyosarcoma

Erika A. Dobrota, Mohammad Reza Saadatzadeh, Barbara J. Bailey, Keiko E. Kreklau et autres

Abstract Primary intraosseous rhabdomyosarcoma (IORMS) is a rare, metastatic, spindle cell-like rhabdomyosarcoma (RMS) subset that occurs in craniofacial bones and less commonly in long bones, or pelvis. IORMS patients typically succumb to the disease within 15 months of diagnosis. This disease is …

us (code pays fourni par la source)

Letter by Ferguson regarding article, “Revenues, costs, and contribution margins of major inpatient cardiovascular procedures within the Medicare population”

Michael J. Ferguson

us (code pays fourni par la source)

Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology

Janet Sybil Biermann, Angela C. Hirbe, Shivani Ahlawat, Nicholas Matthew Bernthal et autres

Ewing sarcoma and osteosarcoma constitute 36% of all primary bone cancers. However, these 2 subtypes represent the most commonly diagnosed bone cancer types in the pediatric and adolescent population. Although still largely unknown, certain genetic mutations, rearrangements, and/or predisposition syndromes likely play …

us, in, Afrique du Sud (code pays fourni par la source)

CT-derived body composition and differential association with age, TNM stage and systemic inflammation in patients with colon cancer

Allan Matthew Golder, Michael J. Ferguson, Paul J. McMillan, David Mansouri et autres

Low skeletal muscle index/density (SMI/SMD) is prevalent in cancer, adversely prognostic and associated with tumour stage and the systemic inflammatory response (SIR). Age and SMI/SMD has not been widely studied. The present study analyses the association between age and SMI/SMD after adjustment …

gb (code pays fourni par la source)

BIOM-10. EXAMINATION OF GROWTH DIFFERENTIATION FACTOR 15 (GDF15) EXPRESSION AS A POTENTIAL PROGNOSTIC BIOMARKER IN PEDIATRIC BRAIN TUMORS

Elizabeth M. Marlowe, Michael J. Ferguson, Mark S. Marshall, Daniel V. Runco

Abstract BACKGROUND Childhood brain tumors remain a leading cause of death with significant treatment-related morbidity and mortality, including disproportionate rates of altered metabolism, neuropathy, and poor quality-of-life. Growth Differentiation Factor 15 (GDF15), a circulating cytokine released by tissue injury, mediates nausea, vomiting, …

us (code pays fourni par la source)

Diagnostic Conundrum of a Sertoli Cell Tumor in a 2-Year-Old Girl with Peripheral Precocious Puberty and a Café-au-Lait Macule: A Case Report

Lauren A. Ray, Deborah F. Billmire, Michael J. Ferguson, Erica A. Eugster

INTRODUCTION: Ovarian Sertoli cell tumors represent a subset of sex cord stromal tumors and are exceedingly rare in prepubertal children. Here, we report a girl with vaginal bleeding due to a Sertoli cell tumor who was originally thought to have McCune-Albright syndrome …

us (code pays fourni par la source)

Abstract 3953: BET inhibitor increases DNA damage, modulates Wnt signaling, and suppresses osteosarcoma growth in naïve and metastatic disease models

Niknam Riyahi, Pankita H. Pandya, Barbara J. Bailey, Erika A. Dobrota et autres

Abstract Osteosarcoma (OS) is an aggressive bone cancer in pediatric adolescent and young adult patients. Survival rate for metastatic and relapsed OS patients remains dismal at <30%. Additionally, no effective standardized salvage therapy currently exists for these patients, in part, due to …

us (code pays fourni par la source)

Pediatric precision oncology: “better three hours too soon than a minute too late”

Mark S. Marshall, Jennifer L. Ivanovich, Morgan R. Schmitt, Amy E. Helvie et autres

Precision oncology is defined as the selection of an effective treatment for a cancer patient based upon genomic profiling of the patient's tumor to identify targetable alterations. The application of precision oncology toward pediatric cancer patients has moved forward more slowly than …

us (code pays fourni par la source)